Physician profile

Javed Malik

Hematology & Oncology · South Bend, IN

NPI 1457666497

$3,616.33

in general payments reported to CMS, 2019-2025

43 companies · $944 in 2025

The $944 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,330.88
Long Term Medical Supply Or Device Loan$1,279.73
Education$20.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $1,532.60 2022-2025
Genentech USA, INC. $220.37 2019-2025 Venclexta, Itovebi, Tecentriq
Astrazeneca Pharmaceuticals LP $160.60 2019-2025 Lynparza, Imfinzi
E.R. Squibb & Sons, L.L.C. $158.46 2019-2025 Opdivo
Amgen INC. $131.07 2019-2022
Abiomed $118.52 2025
Merck Sharp & Dohme LLC $105.13 2019-2024 Keytruda
Celgene Corporation $102.25 2021-2024 Pomalyst
Janssen Biotech, INC. $97.46 2021-2025 Tecvayli, Talvey
Daiichi Sankyo INC. $66.68 2023-2024 Enhertu
Incyte Corporation $66.28 2022-2025 Monjuvi, Jakafi
Pfizer INC. $63.84 2019-2024
Genzyme Corporation $61.64 2019-2022
Pharmacyclics LLC, An Abbvie Company $56.29 2023 Imbruvica, Epkinly
Emd Serono, INC. $44.37 2023 Bavencio
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Geron Corporation $41.86 2025 Rytelo
Stryker Corporation $40.94 2024 Optablate
Eisai INC. $37.39 2021-2023
Pharmacosmos Therapeutics INC. $35.98 2021
Aveo Pharmaceuticals, INC. $31.72 2021-2024
Kyowa Kirin, INC. $30.53 2021-2022
Seagen INC. $30.45 2021
Adaptive Biotechnologies Corporation $30.00 2025 Clonoseq
Dendreon Pharmaceuticals LLC $25.40 2022
Janssen Pharmaceuticals, INC $24.59 2019-2023 Xarelto
Genmab U.S., INC. $23.55 2024 Tivdak
Stemline Therapeutics INC. $23.04 2023 Orserdu
Jazz Pharmaceuticals INC. $20.44 2025
Sobi, INC $18.50 2022
Abbvie INC. $18.36 2024
Tersera Therapeutics LLC $17.74 2021
Pharmaessentia USA Corporation $17.65 2023 Besremi
Glaxosmithkline, LLC. $17.61 2024 Zejula, Jemperli
Puma Biotechnology, INC. $17.50 2021
Lilly USA, LLC $17.12 2019
Mirati Therapeutics, INC. $16.79 2024 Krazati
Clovis Oncology, INC. $15.23 2019-2020
Array Biopharma INC $14.10 2023 Mektovi, Paxlovid, Braftovi
Karyopharm Therapeutics INC. $13.74 2021
Ipsen Biopharmaceuticals, INC $13.41 2021
Astellas Pharma US INC $12.92 2021
Helsinn Therapeutics (U.S.), INC. $12.12 2019
Amag Pharmaceuticals, INC. $12.09 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Javed Malik

$3,616.33

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $944 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).

https://glasscript.com/doctor/1380612/javed-malik

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.